Two-year analysis of efficacy and safety of deferasirox treatment for transfusional iron overload in sickle cell anemia patients.

Abstract

The efficacy and safety of a 2-year treatment with deferasirox was evaluated in 31 patients with sickle cell anemia and transfusional iron overload. At 24 months, there were significant decreases from baseline in mean serum ferritin (from 2,344.6 to 1,986.3 µg/l; p = 0.040) and in mean liver iron concentration (from 13.0 ± 5.4 to 9.3 ± 5.7 mg Fe/g dry weight; p < 0.001). Myocardial T2* values were normal (>20 ms) in all patients at baseline and did not change significantly over the course of the study. However, there was a significant improvement from baseline in left ventricular ejection fraction at 24 months (62.2-64.6%; p = 0.02). Deferasirox was generally well tolerated with no progressive increases in serum creatinine or renal failure observed. These data confirm that deferasirox is effective in reducing body iron burden in patients with sickle cell anemia and transfusional iron overload.

• Authors: Rodolfo Cancado, Maria Cristina A Olivato, Paula Bruniera, Gilberto Szarf, Roberto de Moraes Bastos, Murilo Rezende Melo, Carlos Chiattone
• Journal: Acta haematologica (Acta Haematol) Vol. 128 Issue 2 Pg. 113-8 ( 2012) ISSN: 1421-9662 [Electronic] Switzerland
• PMID: 22760067 (Publication Type: Clinical Trial, Phase IV, Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2012 S. Karger AG, Basel.

Chemical References

• Benzoates
• Iron Chelating Agents
• Triazoles
• Deferasirox

Topics

• Adolescent
• Adult
• Anemia, Sickle Cell (drug therapy)
• Benzoates (adverse effects, therapeutic use)
• Deferasirox
• Female
• Humans
• Iron Chelating Agents (adverse effects, therapeutic use)
• Iron Overload (drug therapy)
• Male
• Prospective Studies
• Triazoles (adverse effects, therapeutic use)
• Young Adult